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Objectives: Drug development is an expensive process, partly because of the 
required testing for human toxicity and efficacy of drugs. Organ-on-a-chip is a 
multichannel 3D microfluidic cell culture chip that simulates the activities and 
mechanics of entire organs and organ systems. Organ-on-chip is expected to 
reduce the amount of animal testing, and may increase efficiency of drug devel-
opment. For instance, when organ-on-a-chip is used to replace or add to in vivo 
testing experiments, 7.5-10% of drug development costs may be saved. This study 
explores the expected advantages of organ-on-chip technologies as well as poten-
tial barriers to implement. MethOds: Stakeholders (n= 50) in this research were 
employees of pharmaceutical companies (n= 18, 36%), developers of microfluidic 
systems and university employees affiliated with organ-on-a-chip/ microfluidic 
systems development and/or drug development (n= 22, 44%). Stakeholders were 
asked their expert opinions about the potential benefits of organ-on-chip using a 
survey (LimeSurvey), which was based on information previously acquired from 
expert interviews. Results: According to stakeholders, organ-on-a-chip may be 
most promising in basic research stage (90%) or the preclinical stage (88%) of drug 
development. Simple models can be used for target identification (70%) while com-
plex models could lead to replacement of animals (78%). However, head-to-head 
studies are needed to change regulations, leaving organ-on-a-chip as an add-on in 
drug development for now. There are significant differences between stakeholders 
opinions about advantages. Most promising organ-on-chip developments should 
target organs like Liver (20%), heart (18%) and kidney (17%). cOnclusiOns: Organ-
on-a-chip can be a valuable add-on in the drug development process, in particular in 
basic research or preclinical stage of the drug development process. Given the very 
early stage of organ-on-chip technologies, it is hard to predict return on investment.
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Objectives: Understand how medical and pharmacy directors (MDs+PDs) and 
pharmacy and therapeutics (P&T) committees from public and private health 
plans, insurers, and PBMs administer formularies, make formulary decisions today, 
and expected changes for the future. MethOds: Online interactive survey of US 
MDs+PDs. Results: Fifty-four percent of respondents were MDs, the remainder 
mostly pharmacists. Most worked for a health plan (83.6%) and 39.6% of the plans 
were local; 35.4% national; and 25.0% regional and 86% were involved in formulary 
decisions. AMCP-dossiers are: not-required (52.2%), used for back-ups (39.1%) and 
used as a basis for reviews (8.9%). Clinician-administered products (ex. office admin-
istered injections) are always under the medical-benefit (67.3%), no plans exclusively 
under the pharmacy-benefit, the remaining 32.7% determine the benefit using cost-
thresholds; most plans (72.9%) do not anticipate a change, 18.8% expect a change 
before 12-2016, 2.1% before 12-2018. Mental health (MH) products were carved-out 
in 1/3 of plans, conditions with multiple MH therapies required generics first (45%), 
mandatory step-therapy (37.5%) and require care by a psychiatrist (17.5%). Most 
were happy with their pharmacy-benefit design, the most requested changes were 
more restrictive management programs; followed by changes in tiers/co-pays. Most 
respondent didn’t desire a change to their P&T process; desired changes included 
more frequent meetings/time; and the use of Comparative Effectiveness Research. 
Most advisors happy with their plan’s medical-benefit management, the most 
desired changes included integration of benefits/departments and more restrictive 
networks. Top current medical concerns: Cancer/oncology, Diabetes and Hepatitis-C. 
Top current budget concerns Hepatitis-C, Cancer/oncology, and Diabetes. Future 
areas of concern include biosimilars, immunomodulators, cardiovascular/heart dis-
ease; multiple sclerosis; biologics; orphan/rare diseases. cOnclusiOns: Managed 
care uses a variety to tools for formulary managment, including benefit type, man-
datory generics and step-therapy. Understanding how decisions are made today 
and concerns for today and in the future can help guide product development.
PHP83
PHarmaCy infOrmaTiOn sysTEm in saUdi HOsPiTals- HOw far is iT TO 
mEET PHarmaCy BEnEfiT managEmEnT PrOgram rEqUiErmEnTs?
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Objectives: Pharmacy Information System (PIS) in hospital pharmacies can opti-
mize the institutional Pharmacy Benefit Management Program (PBMP) and patients’ 
outcomes if the PIS has high detection and reporting capabilities. The aim of the 
study is to explore and investigate the PIS capabilities in tertiary and secondary 
hospitals in Riyadh city, Saudi Arabia. MethOds: A cross-sectional survey tar-
geted pharmacy mangers in hospital with inpatient and outpatient pharmacies 
in Riyadh City in 2014. The survey gathered information about PIS characteristics 
such as detection capabilities (drug interactions, drug allergy, etc.), drug utilization 
reporting capabilities, and PIS integration with Electronic Medical Record (EMR) 
Computerized Physician Ordered Entry (CPOE). Results: Of 30 hospital pharmacies, 
23 (76.6%) pharmacy managers responded, only 21(70%) hospital pharmacies met 
the inclusion criteria, 15 (71.4%) are governmental and 6 (28.6%) are private hospi-
tals, 18(85.7% ) hospitals have EMR, 19 (90.5%) hospital pharmacies have PIS. Of the 
14(66.67%) hospitals with CPOE, only 9 (64.2%) have CPOE that are integrated with 
inpatient and outpatient PIS. For the PIS capabilities, out of the 21 hospitals; 8 (38.1%) 
were able to detect incorrect dose and duration, 7 (33.3%) for drug-drug interaction, 
5(23.8%) for drug-disease Interaction, 6 (28.6%) for contraindication, 6(28.6%) for the 
pital beds changed significantly in 2007 and 2011. The aim of our study is to assess 
the efficiency of the long-term care system in Hungary, to examine the effect of 
these regulations. MethOds: We used input-oriented Data Envelopment Analysis 
to calculate technical- and scale efficiency. We chose five variables: number of 
beds, average length of stay (inputs), number of discharged patients, amount of 
fee paid by the NHIF, and the number of days (outputs). We examined years 2006 
(N= 109), 2010 (N= 121) and 2013 (N= 111). Units operating with less than 50 bed 
were excluded. Data were collected from databases of the Hungarian National 
Health Insurance Fund. For our calculations we used the DEAP 2.1. Results: In 
these years all of the selected variables were increasing, except the average length 
of stay. Technical efficiency was 94.2% in 2006, 88.6% in 2010 and 95.1% in 2013. 
Scale efficiency was 91.4% in 2006, 90.9% in 2010, 92.7% in 2013. Ratio of technically 
efficient units: 24.8% of units were fully efficient in 2006 (n= 27), 19.8% (n= 24) in 
2010, and 35.1% (n= 39) in 2013. The ratio of units achieved 100% scale efficiency 
was 12.8% (n= 14), 5.8% (n= 7) and 17.1% (n= 19). Almost all units were “increasing 
return to scale”, which means they could increase their level of efficiency, if they 
had larger size (more beds). cOnclusiOns: Based on the results we can say 
that the units have relatively high values in all years. Efficiency scores decreased 
slightly in 2006-2010, but showed improvement in the next three years. We can 
conclude that the Hungarian long-term care needs to reduce the number of units, 
but needs to improve the size of them.
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Objectives: Since 2009, Chinese government has constructed essential medicines 
policy of centralized purchasing, uniform distribution, compulsory use and “zero-
mark-up” (i.e. no-profit) sale for essential medicines in primary care, but the policy 
does not regulate the drugstore. As a result, competition relationship between 
drugstore and primary care has changed in rural China. This study aims to inves-
tigate the competition relationship between drugstore and primary care in rural 
China. MethOds: We collect information of treatment procedure of 1015 patients 
from 18 villages at three counties of Shandong Province in China with different eco-
nomic and geographical environment from January to May 2015 by the household 
investigation, supported by National Natural Science Foundation of China [Grant 
Number 71203124]. Competition relationship between drugstore and primary care is 
measured as growth rate of the number of drugstore and primary care. The indica-
tor of patients’ treatment choice is proportion rate of purchasing pharmaceuticals 
channel. The relationship between competition relationship and patients’ choice 
is identified by interviews with stakeholders such as the leader of County Health 
Bureau and primary care. Results: From 2010 to 2014, the number of drugstore in 
poorest and richest County has increased respectively 2.43 times and 0.18 times. 
However, the number of primary care keeps unchanged. At the same time, the treat-
ment choice of patients including village clinic(46.31%), drugstore(22.17%), county 
hospitals(7.49%), township hospitals(6.60%) and other hospitals(17.44%) . Drugstore 
has become the second biggest pharmaceuticals sale channel in rural china. The 
reason for this issue is the limit of only using essential medicines by no-profit 
sale for primary care but not for drugstore. cOnclusiOns: Essential medicine 
policy has changed the competition relationship of pharmaceutical market in rural 
China, which affects treatment choice of patients. The treatment choice of patients 
is threatening the development of essential medicine in rural China. Keywords: 
essential medicine; competition; drugstore; primary care
HEalTH CarE UsE & POliCy sTUdiEs – formulary development
PHP80
THE UniTEd sTaTEs sPECialTy PHarmaCy PayOr landsCaPE
Brook RA1, Smeeding JE1, Sax MJ2
1The TPG-NPRT, Glastonbury, CT, USA, 2The Pharmacy Group (TPG), Glastonbury, CT, USA
Objectives: Determine how medical and pharmacy directors (MDs+PDs) of US 
health plans, insurers, and PBMs manage specialty pharmaceuticals (SPs). In 
2014 SPs accounted for one-third of spending, up from 23% in 2009. MethOds: 
Managed care (MC) MDs+PDs from public and private plans covering multiple types 
of members completed an online interactive survey of: advisor+plan information; 
use of specialty-pharmacies, and current/future coverage of SPs. Results: Fifty-
four percent of respondents were MDs, the remainder mostly pharmacists. Most 
worked for a health plan (83.6%) and the plans were: 39.6%= local; 35.4%= National; 
25.0%= regional. SP providers were restricted by 53.7% of the plans, of those with 
restrictions: the majority restrict SP provider services to a small set under contract 
(63.0%), 17.4% allow any SP; and 6.5% only restricted products available through mul-
tiple specialty-pharmacies. Plans covered clinician-administered products (injec-
tions/infusions) under the medical-benefit (MB= 67.3%); none exclusively under the 
pharmacy-benefit (PB= 0%); and 32.7% based on cost-thresholds. Most plans (72.9%) 
do not anticipate a change, 18.8% expect a change before 12-2016 and 2.1% prior to 
12-2018. Oral Biologics (OBs) were managed under the PB 78.3%; 10.9% under the 
MB; the other 10.9% based on cost-thresholds. Benefits for OBs are not expected to 
change by 71.1% of the plans, 11.1% were currently making changes; 13.3% expect 
changes prior to 12-2016; and 4.4% before 12-2018. SP and OB co-pays vary by group 
and benefit design and are shifting from fixed to percent co-pays. Responses to open 
ended questions placed SP products at the top causes for concern currently, and 
for the coming years. cOnclusiOns: Expenditures for SP products and the use of 
specialty pharmacy will continue to grow. The environment for MC is undergoing a 
series of changes, and payor medical directors and pharmacy directors, who com-
monly serve as P&T Committee members will guide how changes to benefit and 
plan design are implemented in the future.
